(Q37757660)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Global tuberculosis drug development pipeline: the need and the reality (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Andrew Nunn

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

Christian Lienhardt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Zhenkun Ma

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Xiexiu Wang

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

18 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

9731

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

2100-2109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20488518%20AND%20SRC:MED&resulttype=core&format=json

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

New vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

The action of antituberculosis drugs in short-course chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Interactions among drugs for HIV and opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Treatment outcomes of patients with HIV and tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Long term efficacy of DOTS regimens for tuberculosis: systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

The HIV-associated tuberculosis epidemic--when will we act?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

A dynamic reinfection hypothesis of latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Fluoroquinolones for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Oxazolidinone antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Interspecies pharmacokinetics and in vitro metabolism of SQ109.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Challenges in tuberculosis drug research and development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Building clinical trials capacity for tuberculosis drugs in high-burden countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

The quest for biomarkers in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021

Rediscovering the sweet spot in drug discovery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-9

7 January 2021